Bisphenol A (BPA) is a known environmental estrogen that is used as the monomer to manufacture polycarbonate plastic, the resin that is used as linings for most food and beverage cans, as dental sealants, and as an additive in other widely used consumer products. BPA is one of the highest-volume chemicals produced worldwide; global BPA capacity in 2003 was 2,214,000 metric tons (\> 6.4 billion lb), with 6--10% growth in demand expected per year ([@b12-ehp0113-000926]). Heat and contact with either acidic or basic compounds accelerate hydrolysis of the ester bond linking BPA molecules in polycarbonate and resins. Specifically, heating of cans to sterilize food, the presence of acidic or basic food or beverages in cans or poly-carbonate plastic, and repeated washing of polycarbonate products have all been shown to result in an increase in the rate of leaching of BPA ([@b11-ehp0113-000926]; [@b17-ehp0113-000926]; [@b35-ehp0113-000926]; [@b43-ehp0113-000926]; [@b42-ehp0113-000926]; [@b65-ehp0113-000926]; [@b70-ehp0113-000926]). In addition, another potential source of human exposure is water used for drinking or bathing. Studies conducted in Japan ([@b45-ehp0113-000926]) and in the United States ([@b18-ehp0113-000926]) have shown that BPA accounts for most estrogenic activity that leaches from landfills into the surrounding ecosystem.

Convincing evidence that there is widespread exposure to BPA is shown by the finding of [@b14-ehp0113-000926] that 95% of urine samples from people in the United States examined by the Centers for Disease Control and Prevention (CDC) have measurable BPA levels \[range, 0.4 ppb (10th percentile) to 8 ppb (95th percentile); median = 1.3 ppb\]. As described by [@b14-ehp0113-000926], these levels are consistent with findings from other countries. For example, levels of unconjugated (parent) BPA in human blood and tissues are also in the same 0.1--10 ppb range ([@b38-ehp0113-000926]; [@b76-ehp0113-000926]) detected by [@b14-ehp0113-000926] in urine. Because there is evidence that BPA is rapidly metabolized ([@b87-ehp0113-000926]), these finding suggest that human exposure to significant amounts of BPA must be continuous and via multiple sources. A relationship between blood levels of BPA and body fat in women has been reported ([@b79-ehp0113-000926]).

In this commentary, we document for the scientific, public health, and regulatory communities that exposure of experimental animals to "low doses" of BPA, which result in tissue levels within and even below the range of human exposure, has been related to adverse effects in a large number of recently published studies. A recent case--control study reporting that blood levels of BPA are related to ovarian disease in women ([@b79-ehp0113-000926]) adds to our concern. A large number of *in vitro* studies show that effects of BPA are mediated by both genomic and nongenomic estrogen-response mechanisms, with disruption of cell function occurring at doses as low as 1 pM or 0.23 ppt ([@b99-ehp0113-000926]). Although the focus of most studies of effects of BPA has been on its estrogenic activity, recent reports indicating the potential to disrupt thyroid hormone action ([@b55-ehp0113-000926]; [@b104-ehp0113-000926]) mean other modes of action must also be considered. Very low part-per-trillion doses of BPA also cause proliferation of human prostate cancer cells via binding to a mutant form of the androgen receptor expressed in a subpopulation of prostate cancer cells ([@b98-ehp0113-000926]), although BPA acts as an androgen antagonist in the presence of the wild-type androgen receptor ([@b49-ehp0113-000926]; [@b67-ehp0113-000926]) and can also block testosterone synthesis ([@b2-ehp0113-000926]). A comprehensive document containing all of the low-dose BPA references, as well as information concerning mechanisms of action, pharmacokinetics, sources of exposure, and exposure levels in humans, is available online ([@b25-ehp0113-000926]).

Our current conclusion that widespread exposure to BPA poses a threat to human health directly contradicts several recent reports from individuals or groups associated with or funded by chemical corporations \[[@b7-ehp0113-000926]; [@b31-ehp0113-000926]; [@b41-ehp0113-000926]; [@b68-ehp0113-000926]\]. For example, a recently published report on BPA prepared by a panel convened by the Harvard Center for Risk Analysis (HCRA), which was funded by the American Plastics Council (APC), concluded that "the weight of the evidence for low-dose effects is very weak" ([@b31-ehp0113-000926]). However, the charge to the HCRA panel, which was to perform a weight-of-the-evidence evaluation of available data on the developmental and reproductive effects of exposure to BPA in laboratory animals, led to an analysis of only 19 of 47 available published studies on low-dose effects of BPA. The deliberations of the HCRA were in 2001--2002, and accordingly, a cut-off date of April 2002 was selected for consideration of the published literature. It is regrettable that the relevance of the analysis was further undermined by a delay of 2.5 years in publication of the report. During the intervening time, between April 2002 and the end of 2004, a large number of additional articles reporting low-dose effects of BPA in experimental animals have been published. The result is that by the end of 2004, a PubMed (National Library of Medicine, Bethesda, MD) search identified 115 published studies concerning effects of low doses of BPA in experimental animals.

The last U.S. Environmental Protection Agency (EPA) risk assessment for BPA was based on research conducted in the 1980s \[[@b39-ehp0113-000926]\]. The most recent risk assessment of BPA was based on a comprehensive review of the scientific literature conducted in 1998 by the European Union, with some selected articles added through 2001, at which time few of the 115 low-dose BPA studies had been published \[[@b22-ehp0113-000926]\]. Below, we describe recent findings concerning mechanisms mediating effects of very low doses of BPA, the adverse effects being reported in animals, and recent findings from human studies. These published findings lead us to strongly recommend that a new risk assessment for BPA be initiated.

The Definition of "Low Dose"
============================

The U.S. EPA considers "low-dose" effects of environmental endocrine-disrupting chemicals to refer to effects being reported for chemicals at doses lower than those used in traditional toxicologic studies conducted for risk assessment purposes. For BPA, the lowest dose studied for risk assessment purposes was 50 mg/kg/day, which is the currently accepted lowest observed adverse effect level (LOAEL) that was used to calculate a reference dose of 50 μg/kg/day based on experiments conducted in the 1980s ([@b39-ehp0113-000926]).

BPA is often described as a very "weak" estrogen because in a few assay systems, such as MCF-7 breast cancer cells in culture, the dose of BPA required to stimulate cell proliferation (\~ 10^−7^ M or 23 ppb) is roughly 100,000 times higher relative to estradiol, which stimulates cell proliferation at approximately 10^−12^ M ([@b96-ehp0113-000926]). This contrasts, however, with the stimulation by BPA of calcium influx in MCF-7 cells that was significant at the lowest dose tested, which was 10^−10^ M or 23 ppt ([@b95-ehp0113-000926]). BPA also stimulated calcium influx and prolactin secretion in rat pituitary tumor cells at the lowest dose tested (10^−12^ M or 0.23 ppt), and the magnitude of the response to BPA was similar to the response to the same dose of estradiol ([@b99-ehp0113-000926]). It is difficult to conceive how a chemical that can alter cell function at concentrations \< 1 ppt can be characterized as a "weak" endocrine disruptor.

Low-dose effects of endocrine-disrupting chemicals such as BPA are mediated by endocrine-signaling pathways that evolved to act as powerful amplifiers, with the result that large changes in cell function can occur in response to extremely low concentrations ([@b97-ehp0113-000926]). Thus, information concerning the *in vivo* potency of estradiol is critical with regard to predicting the *in vivo* bioactivity of chemicals such as BPA. *In vivo* potency of estrogenic chemicals is determined by the affinity of the chemical for the specific type of estrogen receptor (ER) that mediates the effect, the rate of absorption and metabolism, and binding of the chemical to plasma estrogen-binding proteins. The initial interest in low-dose effects of BPA was based on the observation that BPA showed limited binding to plasma estrogen-binding proteins ([@b57-ehp0113-000926]), which results in higher free plasma BPA relative to estradiol. It is well known that it is the free hormone level in blood that is predictive of biologic activity ([@b58-ehp0113-000926]). A much higher free BPA concentration in blood relative to estradiol would not be taken into account in predicting its *in vivo* potency based simply on cell culture studies conducted in culture medium.

Before conducting the first low-dose *in vivo* study with BPA, vom [@b94-ehp0113-000926] found that an increase in size of the fetal mouse prostate occurred in response to an experimental increase in free serum estradiol in fetuses of 0.1 pg/mL serum (0.1 ppt or 0.4 × 10^−12^ M), from 0.2 pg/mL in control fetuses to 0.3 pg/mL free serum estradiol in estrogen-exposed fetuses. Although this finding was initially controversial, other *in vivo* and *in vitro* studies have since confirmed that very low doses of the estrogenic drug diethylstilbestrol (DES) stimulate an increase in size of the fetal mouse prostate ([@b32-ehp0113-000926]; [@b83-ehp0113-000926]). [@b57-ehp0113-000926] predicted the dose of BPA (fed to pregnant mice) that should be biologically active in mouse fetuses based on a comparison of BPA and estradiol in terms of both the relative affinity for nuclear ERs and binding to serum estrogen-binding proteins that effectively restrict estradiol (but not BPA) uptake into cells. This has been referred to as a "physiologic approach" to dose selection (vom [@b89-ehp0113-000926]). [@b57-ehp0113-000926] chose the fetal prostate growth bioassay to test the physiologically based prediction of low-dose estrogenic activity of BPA, although the prediction was that any estrogenic response would be altered by exposure to BPA during early development. [@b57-ehp0113-000926] reported finding an enlarged prostate in male offspring after feeding pregnant mice 2 or 20 μg/kg/day BPA. Because these doses are below the current reference dose, this finding received a considerable amount of attention.

The findings by [@b57-ehp0113-000926] raised a critical question: Why were the estrogenic effects that they observed below the current reference dose not predicted based on traditional toxicologic studies that focused on the toxic effects of very high doses of BPA ([@b56-ehp0113-000926])? The toxicologic approach involves dose selection based on the maximum tolerated dose, which can be described as "top-down dose selection," whereas the physiologic approach used by [@b57-ehp0113-000926] can be described as "bottom-up dose selection" ([@b97-ehp0113-000926]). We show below that there is now overwhelming evidence demonstrating that these different experimental approaches lead to very different conclusions of safety with regard to the current reference dose for BPA of 50 μg/kg/day. Findings based on low-dose studies thus present a strong challenge to the assumptions that form the basis for chemical risk assessments.

Why Did the APC Contract with the HCRA to Write a Report on Low-Dose Effects of BPA?
====================================================================================

The controversy created by reports of findings for BPA and other chemicals at "low doses," and studies funded by chemical corporations that quickly disputed these findings, resulted in the U.S. EPA asking the National Toxicology Program (NTP) to host a meeting in October 2000 on the low-dose issue. The final NTP Low Dose Peer Review report ([@b63-ehp0113-000926]) was summarized by the co-chairs and session organizers ([@b54-ehp0113-000926]).

In contrast to today, at the time of the NTP low-dose meeting there were relatively few published low-dose studies with BPA. However, the NTP report ([@b63-ehp0113-000926]) was critical of some of the industry-funded studies of BPA. For example, one industry-sponsored study ([@b9-ehp0113-000926]) was criticized by the NTP panel ([@b63-ehp0113-000926], p. A9) for not identifying that the body weights and reproductive organ weights of the control animals were significantly different from those of control animals used in the study that it was supposed to replicate ([@b57-ehp0113-000926]), and that the study was not a true replication because of the use of different animal feed. Another industry-funded study that concluded that all findings were not statistically significant ([@b23-ehp0113-000926]) was harshly criticized by the NTP panel as presenting conclusions that were "flawed," "illogical," and "misleading," and the NTP panel concluded that results were, in fact, statistically significant ([@b63-ehp0113-000926], p. A89).

When the initial report of the NTP panel was released, the APC quickly issued a public letter in which the conclusion of the NTP panel---that there was "credible evidence of low-dose effects"---was described as "troubling . . . if not erroneous" ([@b10-ehp0113-000926]). The APC then contracted with the HCRA in 2000, which established a panel of scientists (including coauthor C.H.) to perform a weight-of-the-evidence evaluation of available data on the developmental and reproductive effects of exposure to BPA in laboratory animals. In turn, the HCRA panel focused on 19 published studies of the available 47 publications and, particularly, on the effects of low doses of BPA on development of the reproductive system in male rodents. The conclusions in the panel's published report ([@b31-ehp0113-000926]) were directed to this portion of the literature that was intensively scrutinized, but the wording was promptly interpreted by plastic industry trade organizations as suggesting that a far more complete survey of the BPA literature had been encompassed by the panel's review process ([@b7-ehp0113-000926]; vom [@b88-ehp0113-000926]). As of April 2002, there were 47 available publications that could have been examined in a comprehensive review of all low-dose effects of BPA in all species. Because of the charge to the HCRA panel and its response to that charge, it reviewed 7 of 9 (78%) of the industry-funded published studies, but reviewed only 12 of 38 (38%) of the government-funded studies that were available in the published literature.

Current Status of Literature on Low-Dose Effects of BPA
=======================================================

Of a total of 115 published studies with low doses of BPA below the prior LOAEL of 50 mg/kg/day that we accessed via a PubMed search at the end of December 2004, there have been 94 published studies reporting *in vivo* estrogenic activity of BPA. Of the 94 low-dose studies reporting significant effects, 31 published studies have reported effects caused by doses of BPA at and below the reference dose of 50 μg/kg/day.

Rate of growth and sexual maturation, hormone levels in blood, reproductive organ function, fertility, immune function, enzyme activity, brain structure, brain chemistry, and behavior are all affected by exposure to low doses of BPA. Many of these effects are due to exposure during early development (gestation and/or lactation), but effects due to postweaning-through-adult exposure have also been reported.

A comprehensive review of the rapidly growing literature on adverse health effects of low doses of BPA in vertebrates and invertebrates is beyond the scope of this commentary, but references are available online ([@b25-ehp0113-000926]). We describe below some examples of effects of low doses of BPA in mice and rats.

-   Increased postnatal growth in both males and females occurred at maternal doses between 2.4 and 500 μg/kg/day ([@b33-ehp0113-000926]; [@b34-ehp0113-000926]; [@b61-ehp0113-000926]; [@b78-ehp0113-000926]).

-   Early onset of sexual maturation in females occurred at maternal doses between 2.4 and 500 μg/kg/day ([@b33-ehp0113-000926]; [@b34-ehp0113-000926]; [@b61-ehp0113-000926]).

-   Altered plasma luteinizing hormone levels occurred at a maternal dose of 2 μg/kg/day ([@b2-ehp0113-000926]), and decreased plasma testosterone in males occurred at a maternal dose of 2 μg/kg/day ([@b2-ehp0113-000926]; [@b46-ehp0113-000926]).

-   An increase in prostate size in male offspring occurred at maternal doses between 2 and 50 μg/kg/day ([@b32-ehp0113-000926]; [@b57-ehp0113-000926]; [@b83-ehp0113-000926]). A decrease in daily sperm production and fertility in males was also reported at doses between 0.2 and 20 μg/kg/day due to developmental or adult exposure ([@b3-ehp0113-000926]; [@b16-ehp0113-000926]; [@b74-ehp0113-000926]; vom [@b89-ehp0113-000926]).

-   Stimulation of mammary gland development in female offspring occurred at the very low maternal dose of 0.025 μg/kg/day delivered tonically by an Alzet pump ([@b51-ehp0113-000926]). Significant disruption of the alignment of chromosomes during meiosis was observed in developing oocytes during puberty because of leaching of BPA from polycarbonate drinking bottles at doses between 15 and 70 μg/kg/day ([@b37-ehp0113-000926]), and an increase in mortality of embryos occurred at a maternal dose of 25 μg/kg/day ([@b4-ehp0113-000926]). Disruption of adult estrous cycles occurred at maternal doses between 100 and 500 μg/kg/day ([@b61-ehp0113-000926]; [@b80-ehp0113-000926]).

-   Altered immune function occurred at doses between 2.5 and 30 μg/kg/day ([@b75-ehp0113-000926]; [@b102-ehp0113-000926], [@b101-ehp0113-000926]).

-   A decrease in antioxidant enzymes occurred at the very low dose of 0.2 μg/kg/day in adult males ([@b16-ehp0113-000926]).

-   Changes in the brain include an increase in progesterone receptor mRNA levels at 400 μg/kg/day ([@b29-ehp0113-000926]), ER-α levels at 40 μg/kg/day ([@b5-ehp0113-000926]), and ER-βmRNA levels at 25 μg/kg/day ([@b71-ehp0113-000926]) and a change in brain somatostatin receptors at 400 μg/kg/day ([@b27-ehp0113-000926]).

-   Behavioral effects include hyperactivity at 30 μg/kg/day ([@b40-ehp0113-000926]), an increase in aggressiveness at 2--40 μg/kg/day ([@b28-ehp0113-000926]; [@b46-ehp0113-000926]), altered reactivity to painful or fear-provoking stimuli at 40 μg/kg/day ([@b6-ehp0113-000926]), and impaired learning at 100 μg/kg/day ([@b59-ehp0113-000926]). Developmental exposure to BPA also resulted in a significant change in the locus coeruleus, where BPA at 30 μg/kg/day reversed the normal sex differences in this brain structure and eliminated sex differences in behavior ([@b47-ehp0113-000926]). Developmental exposure decreased maternal behavior at 10 μg/kg/day ([@b66-ehp0113-000926]), altered play and other socio-sexual behaviors at 40 μg/kg/day ([@b6-ehp0113-000926]; [@b20-ehp0113-000926]), and enhanced the behavioral response to drugs such as amphetamine at 40--300 μg/kg/day ([@b1-ehp0113-000926]; [@b77-ehp0113-000926]).

Factors Accounting for the Absence of Significant Effects in Low-Dose BPA Experiments
=====================================================================================

As of the end of 2004, we are aware of 21 studies that report no harm in response to low doses of BPA. Source of funding is highly correlated with positive or negative findings in published articles. For government-funded published studies, 94 of 104 (90%) report significant effects at doses of BPA \< 50 mg/kg/day. No industry-funded studies (0 of 11, or 0%) report significant effects at these same doses ([Table 1](#t1-ehp0113-000926){ref-type="table"}). It is thus reasonable to pose two questions: *a*) Are government-funded scientists under real or perceived pressure to find or publish only data suggesting adverse outcomes? *b*) Are industry-funded scientists under real or perceived pressure to find or publish only data suggesting negative outcomes?

It is important to determine what specific factors, other than just source of funding, are associated with reports of no significant effects of low doses of BPA. In this article we discuss four issues, some of which have became apparent because of findings published after the cutoff date for the literature review in the HCRA report: strain of experimental animal, misinterpretation of finding no significant effects for the positive controls, animal feed, and specific end point examined.

Strain of experimental animal.
------------------------------

The importance of the strain of animal used in low-dose BPA research was acknowledged in the HCRA report ([@b31-ehp0113-000926]) as well as the previous NTP report ([@b63-ehp0113-000926]). The NTP panel emphasized the need to test for the sensitivity of any animal model by including a positive control, such as the well-characterized estrogenic drugs DES and ethinylestradiol, and stated that

> Because of clear species and strain differences in sensitivity, animal model selection should be based on responsiveness to endocrine active agents of concern (i.e., responsive to positive controls), not on convenience and familiarity. ([@b63-ehp0113-000926], p. vii)

A recent study has revealed the very low sensitivity to any estrogen of the Charles-River Sprague-Dawley (CD-SD) rat used in two studies ([@b24-ehp0113-000926]; [@b86-ehp0113-000926]) that were heavily relied on by the HCRA panel in drawing the conclusion "that the negative findings for reproductive endpoints for rats are more compelling than the positive findings" ([@b31-ehp0113-000926]). According to [@b15-ehp0113-000926], rats were purchased by Charles River from Sprague-Dawley in 1950. This colony was continuously subjected to selective breeding for rapid postnatal growth and large litter size, and then in both 1991 and 1997 new colonies were established from selected animals.

[@b100-ehp0113-000926] reported that the CD-SD strain of rat showed some responses to 50-μg/kg/day ethinylestradiol administered for 28 days, and more responses to the very high dose of 200 μg/kg/day. Ethinylestradiol is the potent estrogenic drug used by women in birth control pills at a dose of 0.5 μg/kg/day (based on a body weight of 60 kg). The CD-SD rat thus has a very low sensitivity to ethinylestradiol, because relative to women, it requires 100- to 400-fold higher doses to produce effects. In contrast, the fetal male CF-1 mouse examined in the initial vom Saal laboratory studies with BPA responded to ethinylestradiol with significant changes in adult sperm production and prostate size at a maternal oral dose of 0.002 μg/kg/day ([@b81-ehp0113-000926]). The CF-1 male mouse fetus is thus between 25,000 and 100,000 times more sensitive to ethinylestradiol relative to the CD-SD rat. [@b100-ehp0113-000926] also reported that 600 mg/kg/day BPA was required to see effects in CD-SD rats. This dose is \> 200,000 times higher than the BPA doses used in studies conducted in the vom Saal laboratory ([@b34-ehp0113-000926], [@b57-ehp0113-000926]), and as indicated above, it is also dramatically higher than doses of BPA required to cause effects in \> 90 other low-dose BPA studies conducted with other types of rats, various mouse strains, and other experimental vertebrate and invertebrate animals. There are now many studies that have been conducted with rats other than the CD-SD strain that show low-dose effects of BPA, but very few of these studies were subject to review by the HCRA panel ([@b31-ehp0113-000926]).

All studies with CD-SD rats report the absence of significant effects of low doses of BPA ([Table 1](#t1-ehp0113-000926){ref-type="table"}), although the conclusions in one these studies ([@b23-ehp0113-000926]) were questioned by the NTP panel ([@b63-ehp0113-000926]). If the studies that used the CD-SD rat are eliminated from consideration, 94 of 98 (96%) government-funded studies report significant effects of low doses of BPA, whereas 0 of 8 (0%) industry-funded studies reports significant effects with the same low doses ([Table 1](#t1-ehp0113-000926){ref-type="table"}).

Misinterpretation of the absence of significant findings for the positive controls.
-----------------------------------------------------------------------------------

The very low sensitivity of the CD-SD rat strain to BPA was predicted by its low sensitivity to ethinylestradiol when it was included as a positive control. Two industry-funded studies ([@b9-ehp0113-000926]; [@b13-ehp0113-000926]) were designed with DES included as a positive control, which was reported by industry spokesmen ([@b85-ehp0113-000926]) at a public news briefing about the [@b13-ehp0113-000926] study. A critique \[[@b26-ehp0113-000926]\] pointed out that the positive control, DES, failed to show a difference from the negative controls in each of these studies ([@b9-ehp0113-000926]; [@b13-ehp0113-000926]); however, the authors did not indicate in their published articles that DES had been used as the positive control. Subsequent studies funded by chemical corporations, all of which have reported the absence of significant effects for low doses of BPA, avoided this problem by simply not including a positive control in the experiment.

The NTP panel ([@b63-ehp0113-000926]) commented on the issue regarding

> . . . a study in which the positive control does not produce the expected positive response. The prudent course of action in such cases may be to declare the study inadequate and repeat it, regardless of the experimental outcome in the test groups. ([@b63-ehp0113-000926], pp. 5--10)

The NTP panel went on to note that,

> For those studies that included DES exposure groups, those that showed an effect with BPA showed a similar low-dose effect with DES (e.g., prostate and uterus enlargement in mice), while those that showed no effect with BPA also found no effect with DES.

As articulated by the NTP panel ([@b63-ehp0113-000926]), only by including a known estrogenic chemical, such as DES or ethinylestradiol, as a positive control in an experiment can the reason for the failure to find low-dose estrogenic effects of BPA be determined to be due to either inactivity of the chemical, insensitivity of the model animal, or some other variable, such as the type of feed used.

Disruption of low-dose studies of endocrine-disrupting chemicals by variability in components of commercial animal feed.
------------------------------------------------------------------------------------------------------------------------

A critical issue in experiments concerning effects of low doses of estrogenic chemicals is that a common rodent feed used in toxicologic studies has been reported by investigators at the National Institute of Environmental Health Sciences ([@b82-ehp0113-000926]) to be highly variable in its estrogenic activity. These investigators reported that some batches of this feed were able to interfere with the ability to detect puberty-accelerating effects of DES in female CD-1 mice, due to the feed maximally advancing the age at puberty in control females ([@b82-ehp0113-000926]). The use of this particular feed by [@b13-ehp0113-000926] and [@b86-ehp0113-000926] raises the possibility that endocrine-disrupting components in this feed played a role in the failure of these studies to show low-dose effects of BPA; [@b13-ehp0113-000926] also failed to find significant effects of the positive control DES, whereas [@b86-ehp0113-000926] did not include a positive control. The HCRA panel ([@b31-ehp0113-000926]) relied heavily on both of these studies.

Both the [@b63-ehp0113-000926] and HCRA panels ([@b31-ehp0113-000926]) raised the possibility that the type of feed used in some studies may have affected the results, but the information provided by [@b82-ehp0113-000926] about variability in estrogenic activity in different batches of a feed commonly used in toxicologic studies, and other recent findings regarding variability in endocrine-disrupting components of feed other than phytoestrogens (vom [@b92-ehp0113-000926], [@b91-ehp0113-000926]), was not available for either the NTP or the HCRA panel to review. Thus, it is understandable that the HCRA report could state: "Nor is there compelling evidence that the type of feed administered . . . can explain the negative results reported" ([@b31-ehp0113-000926]).

It is now clear that it is necessary to develop a standard feed that is appropriate for studies involving the examination of end points that are sensitive to estrogenic chemicals, because estrogenic as well as other components of feed can be present in highly variable amounts in different batches; levels of phytoestrogens in plants vary in response to different environmental conditions. The findings reported by [@b82-ehp0113-000926] that effects of DES could be masked by some batches of a commercial feed clearly demonstrate that, without an appropriate positive control, false-negative findings can occur that lead to the false conclusion that even biologically active doses of potent estrogenic drugs such as DES have no effect.

The uterotrophic response is not stimulated by low doses of BPA.
----------------------------------------------------------------

Seven articles have reported that low doses of BPA do not stimulate a uterotrophic response ([@b8-ehp0113-000926]; [@b21-ehp0113-000926]; [@b30-ehp0113-000926]; [@b48-ehp0113-000926]; [@b52-ehp0113-000926]; [@b53-ehp0113-000926]; [@b84-ehp0113-000926]). For example, a dose of 100 mg/kg/day BPA injected subcutaneously was required to stimulate an increase in uterine weight in pre-pubertal CD-1 mice ([@b52-ehp0113-000926]). This is in marked contrast to the fetal CD-1 mouse prostate ([@b32-ehp0113-000926]; [@b83-ehp0113-000926]), testes ([@b46-ehp0113-000926]), mammary glands ([@b51-ehp0113-000926]), and brain ([@b66-ehp0113-000926]), which all respond to doses of BPA at and far below the reference dose of 50 μg/kg/day. In order to assess the effects of low doses of BPA or other estrogenic endocrine-disrupting chemicals on the uterus, more sophisticated approaches are required than just measuring uterine weight ([@b52-ehp0113-000926]; [@b60-ehp0113-000926]).

Implications for Risk Assessments of Low-Dose BPA Effects
=========================================================

As noted above, BPA is a widely used chemical, with a capacity in excess of 6.4 billion lb in 2003. If regulatory agencies were to determine that the actual LOAEL for BPA is below the current reference dose of 50 μg/kg/day, the 15 corporations that manufacture BPA would be affected economically ([@b12-ehp0113-000926]). However, corporations that manufacture products made from BPA would be less affected because alternatives to BPA already exist for many products. Potential economic impacts need to be considered in relation to the implications for human health of the wide range of adverse effects caused by exposure to very low doses of BPA in the animal experiments described above.

Measurements of current human contamination indicate that exposure of human fetuses to BPA already occurs at levels within the range demonstrated to cause adverse effects in fetal rodents ([@b76-ehp0113-000926]). Specifically, [@b103-ehp0113-000926] injected pregnant CD-1 mice subcutaneously on gestation day 17 with 25 μg/kg tritiated BPA; parent (unconjugated) BPA levels in mouse fetuses at 0.5, 2, and 24 hr after administration were 4.20, 0.48, and 0.13 ng/g (ppb), respectively. [@b76-ehp0113-000926] reported that parent BPA levels in human fetal serum ranged from 0.2 to 9.2 ng/mL (ppb), and the median was 2.3 ng/mL (ppb). Many adverse effects have been reported in offspring due to maternal doses of ≤25 μg/kg/day in mice.

That the adverse effects being observed at low doses of BPA in animal experiments should be of concern with regard to human health is shown by a study comparing BPA levels in nonobese and obese women in Japan who had normal ovarian function or polycystic ovarian disease. In this case--control study [@b79-ehp0113-000926] reported significantly higher blood levels of BPA both in obese women and in women with polycystic ovarian disease. These findings suggest that the adverse effects due to exposure to low doses of BPA in experimental animals may be predictive of adverse effects in adult humans.

The implications of these results extend beyond BPA, because they may lead to requirements that hazard assessments be designed to detect analogous low-dose impacts of other chemicals. Acknowledgment of the existence of the large number of studies showing unique low-dose effects of BPA could lead to the demand that, in designing studies to assess the hazards of all chemicals for risk assessment purposes, a wider range of doses must be examined, as opposed to only a few very high doses based on the maximum tolerated dose. This would require accepting that extrapolation from data on effects at very high doses (based on the linear-threshold model) is not valid for endocrine-disrupting chemicals (vom [@b93-ehp0113-000926]; [@b97-ehp0113-000926]).

We posed above the question concerning why a large number of estrogenic effects have been observed in studies that examined low doses of BPA, but these effects were not predicted based on traditional toxicologic studies that focused on the toxic effects of very high doses of BPA. When evidence of a non-monotonic, inverted-U dose--response relationship is found in a toxicologic study, the results are often identified as not showing a dose--response relationship. Although findings in toxicologic studies that occur within a low-dose range but not at higher doses are typically discounted or, at best, considered to be rare, just for BPA there are currently 11 *in vivo* and *in vitro* examples of unique effects seen at low doses but not at higher doses (e.g., [@b25-ehp0113-000926]; [@b64-ehp0113-000926]; [@b98-ehp0113-000926]; [@b97-ehp0113-000926]; [@b99-ehp0113-000926]).

The inverted-U dose--response phenomenon shows that dose selection is critical in studies of chemicals such as BPA, and older toxicologic studies that just examined a few very high doses are not relevant for assessing the possibility of unique effects that only occur within a specific low-dose range. The mechanisms mediating qualitative changes in response over a wide range of doses are now being elucidated at multiple levels, such as gene-response profile ([@b19-ehp0113-000926]), changes in tissue expression of receptors ([@b32-ehp0113-000926]), and changes in neuroendocrine feedback systems ([@b73-ehp0113-000926]; [@b80-ehp0113-000926]). Low doses of a hormone can stimulate a response, whereas much-higher doses inhibit the same response, and this phenomenon is so well established that it is used in clinical endocrinology to treat diseases ([@b44-ehp0113-000926]; [@b97-ehp0113-000926]). Although endocrinologists find it plausible that there are unique effects caused by low doses of a chemical with hormonal activity that might not be observed at much higher doses, this has not been recognized by regulatory agencies involved in risk assessments.

It is important to keep in mind that traditional toxicologic testing of chemicals for regulatory purposes requires examination of only a few very high doses of a chemical, which often do not exceed 50-fold below the maximum tolerated dose (vom [@b93-ehp0113-000926]). The maximum tolerated dose of BPA is very high (\~ 1,250,000 μg/kg/day; [@b56-ehp0113-000926]; [@b39-ehp0113-000926]). In contrast, a wide range of adverse effects in 31 published studies have been reported in offspring due to administering pregnant mice and rats doses of BPA 25,000 times lower than the maximum tolerated dose ([@b25-ehp0113-000926]). The conclusion from these published findings is that examining only a 50-fold dose range on the basis of the maximum tolerated dose is a seriously flawed approach for assessing adverse effects of chemicals that are mediated by highly sensitive endocrine-response mechanisms.

Regulatory agencies readily accept that the predicted reference dose is actually "safe" without ever requiring that this dose be verified in an experiment to cause no adverse effects (vom [@b93-ehp0113-000926]; [@b97-ehp0113-000926]). Regulatory agencies need to acknowledge that there is now overwhelming evidence for adverse effects of one of the highest-volume chemicals in commerce below the previously predicted "safe" daily dose for humans. This should lead to the requirement that new risk assessments be conducted to reevaluate the safety of other chemicals, in addition to BPA.

Conclusions and Recommendations
===============================

In summary, a comprehensive up-to-date analysis by regulatory agencies is needed to evaluate the potential hazards to humans from exposure to BPA at doses below the prior LOAEL of 50 mg/kg/day; low doses of BPA have now been reported to alter brain chemistry and structure, behavior, the immune system, enzyme activity, the male reproductive system, and the female reproductive system in a variety of animals, including snails, fish, frogs, and mammals. There are also a number of *in vitro* studies showing that the particular type of ER (α or β) and the specific coregulators present in cells can markedly influence the dose of BPA required to stimulate a response (e.g., [@b72-ehp0113-000926]). This is consistent with estrogen-responsive tissues within the same animal showing marked differences in the dose of BPA required to elicit a response.

Not all effects of BPA are mediated by the classical nuclear ERs (α and β). Very low part-per-trillion doses of BPA can stimulate responses in cultured mouse pancreas cells, rat pituitary tumor cells, and human breast cancer cells via rapid induction of calcium uptake ([@b69-ehp0113-000926]; [@b95-ehp0113-000926]; [@b99-ehp0113-000926]); these same low doses of BPA stimulate proliferation in mouse ([@b32-ehp0113-000926]) and human ([@b98-ehp0113-000926]) prostate cells in culture. Nongenomic cell signaling systems involve serial activation of kinases via ligand binding to receptors associated with the cell membrane, and these pathways are known to have tremendous amplifying capacity.

In the now outdated perspective of the HCRA report ([@b31-ehp0113-000926]), it was stated that "In the case of BPA the only proposed mechanism for low-dose effects is through modulation of the \[nuclear\] estrogen receptor." Instead, the recent findings concerning the multiple mechanisms of action of BPA show that at concentrations \< 1 ppt, BPA activates receptors associated with the plasma membrane of selected target cells. As the BPA "dose at target" increases, various responses in the same or different cells are activated or inhibited ([@b50-ehp0113-000926]), with the specific dose required being dependent on the subtype of nuclear ER and specific coactivators or coinhibitors that are present. At even higher concentrations (parts per billion to parts per million), inhibition of androgen-stimulated and thyroid-hormone--stimulated responses can also occur. That the integrated output across a 1-million-fold dose range can be nonmonotonic (inverted-U shape) is thus not unexpected by scientists who study hormones and hormonally active drugs or chemicals ([@b97-ehp0113-000926]). Regulatory agencies that conduct risk assessments have not addressed the implications of nonmonotonic dose--response curves for endocrine-disrupting chemicals with regard to the linear-threshold model currently used to predict "safe" doses for humans.

The *in vitro* findings at low (and even sub) part-per-trillion doses of BPA have to be viewed in relation to potential effects of free (unconjugated and unbound) BPA levels in human blood. Data from numerous studies show that unconjugated BPA in human blood and tissues is in the low part-per-billion range ([@b25-ehp0113-000926]) and that BPA shows limited binding to human plasma binding proteins that regulate the uptake of estrogenic chemicals into tissues ([@b58-ehp0113-000926]). Importantly, new analytical methods have been developed since the published literature was reviewed in 1998 for the last BPA risk assessment conducted by the European Union ([@b22-ehp0113-000926]). These new methods have now made it possible to detect BPA in blood within the range that it shows biologic activity, which was not previously the case. There is thus convincing evidence that biologically active levels of BPA in human blood are above the range that has been demonstrated to cause changes in function in human tissues based on *in vitro* studies.

The literature we reviewed shows that the rate of leaching from commonly used BPA-containing products (the lining of tin cans and polycarbonate food and beverage containers) is high enough to result in adverse effects in laboratory animals ([@b70-ehp0113-000926]). These recently published findings indicate that the accepted migration limit \[recently set by the European Union ([@b22-ehp0113-000926])\] of 30 ppb BPA from polycarbonate or resins into food and beverages is not sufficiently protective of human health. The case--control study reporting that ovarian disease in Japanese women is related to blood levels of BPA provides a first confirmation of this prediction in adult humans ([@b79-ehp0113-000926]).

Almost one-half of the low-dose BPA studies have been published in just the last 2 years, and there were only five published low-dose BPA studies as of 1998 when the initial comprehensive literature search was conducted for the last risk assessment conducted by the European Union ([@b22-ehp0113-000926]). A thorough analysis of the entire published low-dose BPA literature associated with a new risk assessment by regulatory agencies that takes into account the issues discussed here and elsewhere is now warranted (vom [@b88-ehp0113-000926]; [@b93-ehp0113-000926]; vom [@b92-ehp0113-000926], [@b91-ehp0113-000926], in press; [@b97-ehp0113-000926]). It is important that a reexamination of the BPA low-dose literature include a discussion of the requirement for appropriate positive controls, which was identified by the NTP panel as a significant problem in studies claiming to find no low-dose effects.

The initial NTP review concerning BPA as a carcinogen concluded that "there was no convincing evidence that \[BPA\] was carcinogenic," because the background level of cancer was high in untreated males ([@b62-ehp0113-000926]). This conclusion has been criticized by a scientist in the NTP: [@b36-ehp0113-000926] concluded that, if these findings ([@b62-ehp0113-000926]) were officially reanalyzed based on the approach to interpreting cancer in animal studies used today, BPA would be interpreted as being associated with an increase in tumors of blood cells, the testes, and the mammary glands.

In summary, a new risk assessment is needed to establish a new LOAEL and a new reference dose for BPA based on the extensive new information from low-dose studies. In addition, the low-dose literature for BPA and other endocrine-disrupting chemicals shows that regulatory agencies need to begin the process of reevaluating the assumptions that provide the basis for the linear-threshold model used in risk assessments.
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###### 

Biased outcome due to source of funding in low-dose *in vivo* BPA research as of December 2004.

                          All studies   CD-SD rat studies   All studies except CD-SD rats                       
  ----------------------- ------------- ------------------- ------------------------------- --------- --------- ---------
  Government              94 (90.4)     10 (9.6)            0 (0%)                          6 (100)   94 (96)   4 (4)
  Chemical corporations   0 (0)         11 (100)            0 (0%)                          3 (100)   0 (0)     8 (100)

Values shown are no. (%).
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